RIVASTIGMINE AML PATCH 5 rivastigmine 4.6 mg/24 hours transdermal drug delivery system sachet

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

rivastigmine, Quantity: 9 mg

Inapatikana kutoka:

Arrotex Pharmaceuticals Pty Ltd

INN (Jina la Kimataifa):

Rivastigmine

Dawa fomu:

Drug delivery system, transdermal

Tungo:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Njia ya uendeshaji:

Transdermal

Vitengo katika mfuko:

30 transdermal drug delivery systems, 7 transdermal drug delivery systems

Dawa ya aina:

(S4) Prescription Only Medicine

Matibabu dalili:

RIVASTIGMINE AML is indicated for the treatment of patients with mild to moderate dementia of the Alzheimer's type.

Bidhaa muhtasari:

Visual Identification: Circular 5cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 4.6 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Idhini hali ya:

Licence status A

Idhini ya tarehe:

2016-01-12